Kidney transplantation. Kidney transplant status
Conditions
Interventions
Intervention 1: Intervention group: Patients will receive 10mg (Gloripa) of empagliflozin oral once daily for six months with standard treatments. Intervention 2: Intervention group: Patients will rec
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: patients with kidney transplantation aged 18 to 80 consented patients
Exclusion criteria
Exclusion criteria: Pregnancy Lactation Liver failure Heart failure Contraindications of empagliflozin or dapagliflozin Systolic blood pressure less than 100 Autoinflammatory diseases Malignancy Diabetes mellitus Contraindications of dapagliflozin Systolic blood pressure more than 180 mm Hg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute organ rejection. Timepoint: At the baseline and 2, 4, 8, 12, and 16 weeks after intervention. Method of measurement: biopsy.;Kidney adverse events of CNI. Timepoint: At the baseline and 2, 4, 8, 12, and 16 weeks after intervention. Method of measurement: Measurement of serum creatinine, GFR, and albumin.;Liver adverse events of CNI. Timepoint: At the baseline and 2, 4, 8, 12, and 16 weeks after intervention. Method of measurement: Measurement of liver enzyme and albumin levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of new diabetes mellitus following kidney transplantation. Timepoint: At baseline and 2, 4, 8, 12, and 16 weeks after the intervention. Method of measurement: Measurement of hemoglobin A1C, fasting blood sugar, and two-hour blood sugar. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Afshin Gharekhani
Tabriz University of Medical Sciences
Outcome results
None listed